

Simplify SARS-CoV-2 testing

The BD Veritor™ Plus System
Rapid, reliable SARS-CoV-2 testing at the point of care

The portable, easy-to-use BD Veritor™ Plus System provides reliable SARS-CoV-2 results in 15 minutes

This product is only to be used under an Emergency Use Authorization

VWR™ part of avantor
order on VWR.COM

BD

Be ready for SARS-CoV-2 testing

When your patients are in need of fast, reliable SARS-CoV-2 testing, turn to the BD Veritor™ Plus System. Offering lab-quality results at the point of care, in a simple-to-operate, handheld instrument.

Simplify the testing process

- Easy operation and 1-button functionality may potentially reduce manual test processing errors
- Enables intuitive sample processing with prefilled, unitized tubes color-coded by reagent or assay type

Achieve fast, reliable results

- Displays easy-to-read digital results for SARS-CoV-2 in 15 minutes
- Records results on secured drive
- Advanced particle technology enhances sensitivity by using a proprietary process to produce highly stable, modified colloidal metal particles, helping improve test performance*
- Adaptive read technology helps improve specificity to reduce false-positive results by compensating for background and nonspecific binding

Provide workflow efficiency

- Adapts easily to your workflow by offering 2 operational modes
  - **Walk away:** Test device is inserted immediately into Analyzer, enabling staff to multitask while sample incubates
  - **Analyze now:** Test device is inserted after incubation time is complete, allowing batches of samples to be tested

Provide result traceability

- Download and display LOT number, Patient/specimen ID, Operator ID and test records with BD Veritor™ InfoScan module
- Offers result-printing capabilities via USB port

*in comparison to visually read tests

1. BD Veritor System for Rapid Detection of SARS-CoV-2 package insert. Franklin Lakes, NJ: Becton, Dickinson and Company.

Clinical Performance[1]

Positive Percent Agreement (PPA)	Negative Percent Agreement (NPA)
84%	**100%**
(95% Confidence Interval (C.I.), 67%–93%)	(95% Confidence Interval (C.I.), 98–100%)

Negative results do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient's recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management. For additional information, please refer to the HCP fact sheet.

- This test has not been FDA cleared or approved
- This test has been authorized by FDA under an EUA for use by authorized laboratories
- This test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens
- This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Ordering information	VWR Cat. no.	Qty.
BD Veritor™ System for Rapid Detection of SARS-CoV-2	76423-716	30 tests
Other BD Veritor™ related products		
BD Veritor™ System Flu A+B Moderately complex	10031-434	30 tests
BD Veritor™ System Flu A+B CLIA-waived kit	10031-432	30 tests
BD Veritor™ System RSV CLIA-waived kit	10124-732	30 tests
BD Veritor™ System RSV Moderately complex	10031-438	30 tests
BD Veritor™ System Group A Strep CLIA-waived kit	10124-734	30 tests
BD Veritor™ Plus System Analyzer	75846-772	1
BD Veritor™ InfoScan module 1	75846-752	1
USB printer cable 1	75846-754	1

0920 Lit. No. 020119W

BD

BD Life Sciences, Sparks, MD 21152-0999 U.S.